Replies to post #58139 on Amarin Corp Plc (AMRN)

[FishyFingers]

Thanks. Seeing that Lipitor's primary Indications are Prevention Of Cardiovascular Disease and Hyperlipidemia, I imagine that Vascepa's will be Prevention Of Cardiovascular Disease and Mixed Dyslipidemia.

http://www.rxlist.com/lipitor-drug/indications-dosage.htm

Would still be nice to get Vascepa approved for use as a non-HDL-C lowering agent in the ANCHOR patient population while we are waiting for R-IT, if the FDA are not going to approve ANCHOR as a high TG lowering agent.